David C. Nickle

David C. Nickle

Auto-generated profile, based on publicly available information

David C. Nickle

Affiliations UW School of Global Health, Seattle, Washington, United States of America, Monoceros Biosystems, San Diego, California, United States of America

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
KVKim Valette
Kim Valette
ZLZhonglin Li
Zhonglin Li
VBValentin Bon-Baret
Valentin Bon-Baret
ACArnaud Chignon
Arnaud Chignon
JBJean-Christophe Bérubé
Jean-Christophe Bérubé
YBYohan Bossé
Yohan Bossé
To identify candidate causal genes of asthma, we performed a genome-wide association study (GWAS) in UK Biobank on a broad asthma definition (n = 56,167 asthma cases and 352,255 controls). We then carried out functional mapping through transcriptome-wide association studies (TWAS) and Mendelian randomization in lung (n = 1,038) and blood (n = 31,684) tissues. The GWAS reveals 72 asthma-associated loci from 116 independent significant variants (PGWAS < 5.0E-8). The most significant lung TWAS gene on 17q12-q21 is GSDMB (PTWAS = 1.42E-54). Other TWAS genes include TSLP on 5q22, RERE on 1p36, CLEC16A on 16p13, and IL4R on 16p12, which all replicated in GTEx lung (n = 515). We demonstrate that the largest fold enrichment of regulatory and functional annotations among asthma-associated variants is in the blood. We map 485 blood eQTL-regulated genes associated with asthma and 50 of them are causal by Mendelian randomization. Prioritization of druggable genes reveals known (IL4R, TSLP, IL6, TNFSF4) and potentially new therapeutic targets for asthma.

22 March 2021 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
HZHailong Zhao
Hailong Zhao
DNDavid C. Nickle
David C. Nickle
ZZZhen Zeng
Zhen Zeng
PLPierra Y. T. Law
Pierra Y. T. Law
MWMark H. Wilcox
Mark H. Wilcox
JLJunhua LI
Junhua LI
Introduction Clostridioides (Clostridium) difficile infection, the leading cause of healthcare-associated diarrhea, represents a significant burden on global healthcare systems. Despite being a global issue, information on C. difficile from a global perspective is lacking. The aim of this study is to model the global phylogeography of clinical C. difficile. Methods Using samples collected from the MODIFY I and II studies (NCT01241552, NCT01513239), we performed whole-genome sequencing of 1501 clinical isolates including 37 novel sequence types (STs), representing the largest worldwide collection to date. Results Our data showed ribotypes, multi-locus sequence typing clades, and whole-genome phylogeny were in good accordance. The clinical C. difficile genome was found to be more conserved than previously reported (61% core genes), and modest recombination rates of 1.4–5.0 were observed across clades. We observed a significant continent distribution preference among five C. difficile clades (Benjamini-Hochberg corrected Fisher’s exact test P < 0.01); moreover, weak association between geographic and genetic distance among ribotypes suggested sources beyond healthcare-related transmission. Markedly different trends of antibiotic susceptibility among lineages and regions were identified, and three novel mutations (in pyridoxamine 5′-phosphate oxidase family protein: Tyr130Ser, Tyr130Cys, and a promoter SNP) associated with metronidazole-reduced susceptibility were discovered on a nim-related gene and its promotor by genome-wide association study. Toxin gene polymorphisms were shown to vary within and between prevalent ribotypes, and novel severe mutations were found on the tcdC toxin regulator protein. Conclusion Our systematic characterization of a global set of clinical trial C. difficile isolates from infected individuals demonstrated the complexity of the genetic makeup of this pathogenic organism. The geographic variability of clades, variability in toxin genes, and mutations associated with antibiotic susceptibility indicate a highly complex interaction of C. difficile between host and environment. This dataset will provide a useful resource for validation of findings and future research of C. difficile.

24 June 2020 in mSphere
Verified
Journal Article
Open access
PDF file
JSJudong Shen
Judong Shen
DMDevan V Mehrotra
Devan V Mehrotra
MDMary Beth Dorr
Mary Beth Dorr
ZZZhen Zeng
Zhen Zeng
JLJunhua LI
Junhua LI
PSPeter Shaw
Peter Shaw
Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin B, indicated to prevent recurrence of C. difficile infection (rCDI) in high-risk adults receiving antibacterial treatment for CDI. An exploratory genome-wide association study investigated whether human genetic variation influences bezlotoxumab response. DNA from 704 participants who achieved initial clinical cure in the phase 3 MODIFY I/II trials was genotyped. Single nucleotide polymorphisms (SNPs) and human leukocyte antigen (HLA) imputation were performed using IMPUTE2 and HIBAG, respectively. A joint test of genotype and genotype-by-treatment interaction in a logistic regression model was used to screen genetic variants associated with response to bezlotoxumab. The SNP rs2516513 and the HLA alleles HLA-DRB1*07:01 and HLA-DQA1*02:01, located in the extended major histocompatibility complex on chromosome 6, were associated with the reduction of rCDI in bezlotoxumab-treated participants. Carriage of a minor allele (homozygous or heterozygous) at any of the identified loci was related to a larger difference in the proportion of participants experiencing rCDI versus placebo; the effect was most prominent in the subgroup at high baseline risk for rCDI. Genotypes associated with an improved bezlotoxumab response showed no association with rCDI in the placebo cohort. These data suggest that a host-driven, immunological mechanism may impact bezlotoxumab response. Trial registration numbers are as follows: NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II). IMPORTANCEClostridium difficile infection is associated with significant clinical morbidity and mortality; antibacterial treatments are effective, but recurrence of C. difficile infection is common. In this genome-wide association study, we explored whether host genetic variability affected treatment responses to bezlotoxumab, a human monoclonal antibody that binds C. difficile toxin B and is indicated for the prevention of recurrent C. difficile infection. Using data from the MODIFY I/II phase 3 clinical trials, we identified three genetic variants associated with reduced rates of C. difficile infection recurrence in bezlotoxumab-treated participants. The effects were most pronounced in participants at high risk of C. difficile infection recurrence. All three variants are located in the extended major histocompatibility complex on chromosome 6, suggesting the involvement of a host-driven immunological mechanism in the prevention of C. difficile infection recurrence.

1 June 2025 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
QCQing Chen
Qing Chen
MWMarissa Wisman
Marissa Wisman
KNKingsley Okechukwu Nwozor
Kingsley Okechukwu Nwozor
DSDon D Sin
Don D Sin
Philippe JoubertPhilippe Joubert
Philippe Joubert
Irene HeijinkIrene Heijink
Irene Heijink
We show that overexpression of HHIP protected from cigarette smoke-induced epithelial-to-mesenchymal transition and promoted epithelial regeneration via epithelial-mesenchymal cross talk in non-COPD controls. Thus, the lower expression of HHIP in airway epithelial cells from patients with COPD may contribute to abnormal epithelial repair in both proximal and distal parts of the lungs of patients with COPD.

16 June 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
MNM.L. Koloko Ngassie
M.L. Koloko Ngassie
MVMaaike De Vries
Maaike De Vries
TBT. Borghuis
T. Borghuis
WTWim Timens
Wim Timens
DSDon D. Sin
Don D. Sin
CBCorry-Anke Brandsma
Corry-Anke Brandsma
Introduction: Extracellular matrix (ECM) remodelling has been associated with chronic lung diseases. However, information about specific age-associated differences in lung ECM is currently limited. In this study we aimed to identify and localize age-associated ECM differences in human lung using comprehensive transcriptomic, proteomic and immunohistochemical analyses. Methods: Our previously identified age-associated gene expression signature of the lung was re-analysed limiting it to an aging signature based on 270 control patients (37-80 years) and focused on the Matrisome core geneset using geneset enrichment analysis. To validate the age-associated transcriptomic differences on protein level, we compared the age-associated ECM genes (F <0.05) with a profile of age-associated proteins identified from a lung tissue proteomics dataset from 9 control patients (49-76 years) (FDR<0.05). Extensive immunohistochemical analysis was used to localize the age-associated ECM differences in lung tissues from control patients (9-82 years). Results: Comparative analysis of transcriptomic and proteomic data identified 7 ECM proteins with higher expression with age at both gene and protein level: COL1A1, COL6A1, COL6A2, COL14A1, FBLN2, LTBP4 and LUM. With immunohistochemistry we demonstrated higher protein expression with age for COL6A2 in whole tissue, parenchyma, airway wall and blood vessel, for COL14A1 in bronchial epithelium and blood vessel, and for FBLN2 and COL1A1 in lung parenchyma. Conclusion: Our study revealed that higher age is associated with lung ECM remodelling, with specific differences occurring in defined regions within the lung. These differences may affect lung structure and physiology with aging and as such may increase susceptibility for developing chronic lung diseases. Key messages: What is already known on this topic: summarise the state of scientific knowledge on this subject before you did your study and why this study needed to be done. ❖ In animal models, it has been demonstrated that aging alters the composition of the lung ECM, with more deposition of collagen and degradation of elastin. Similar ECM differences have been observed in age-associated chronic lung diseases, including COPD; moreover, we observed in lung tissue that several ECM genes associate differently with age in COPD patients compared to non-COPD controls(1). Detailed knowledge on age-associated changes in specific ECM proteins as well as regional differences within the lung is lacking. What this study adds: summarise what we now know as a result of this study that we did not know before. ❖ We identified 7 age-associated ECM proteins i.e. COL1A1, COL6A1, COL6A2 COL14A1, FBLN2, LTBP4 and LUM with higher transcript and protein levels in human lung tissue with age. Extensive immunohistochemical analysis revealed significant age-associated differences for 3 of these ECM proteins in specific compartments of the lung, with the most notable differences in the blood vessels and parenchyma. How this study might affect research, practice, or policy: s ummarise the implications of this study . ❖ The identification of age-associated differences in specific human lung ECM proteins lays a new foundation for the investigation of ECM differences in age-associated chronic lung diseases. Additionally, examining the function of these age-associated ECM proteins and their cellular interactions in lung injury and repair responses may provide novel insight in mechanisms underlying chronic lung diseases.

14 August 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DNDavid C. Nickle
David C. Nickle
The study of genetic diversity has a rich history, as it serves as the foundation upon which evolutionary processes act. Numerous methods have been developed to quantify genetic variation within and among populations. While some methods focus solely on allele frequencies, others assess branching patterns within phylogenetic clades without considering genetic distances. Here we introduce the P roportional Diversity L ikelihood R atio Statistic (PLR), a novel method that integrates genetic distances with phylogenetic tree structure to provide a comprehensive measure of genetic diversity. This method evaluates the likelihood of observed genetic data under models with constrained and unconstrained diversity, offering a robust statistical framework for testing hypotheses about genetic differentiation. The PLR approach is broadly applicable, from assessing immune repertoire diversity, such as B-cell diversity before and after vaccination, to evaluating tumor genetic diversity before and after treatment. By combining genetic distance and tree topology, PLR enables deeper insights into evolutionary dynamics and population structure. We demonstrate the use of this approach on SARS-CoV-2 sequences from two different time frames and found that diversity maybe waning. Moreover, we applied PRL to chronic lymphocytic leukemia (CLL) data, revealing that with temporally order sequences from with treatment we do not see a significant drop in diversity.